

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Addiese: COMMISSIONER FOR PATENTS P O Box 1450 Alexandra, Virginia 22313-1450 www.wepto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/518,372	12/28/2004	Yasushi Shioya	264048US0PCT	8910	
23859 97590 03U20099 OBLON, SPIVAK, MCCLELLAND MAIER & NEUSTADT, P.C. 1940 DUKE STREET			EXAM	EXAMINER	
			PADEN, CAROLYN A		
ALEXANDRIA, VA 22314			ART UNIT	PAPER NUMBER	
			1794		
			NOTIFICATION DATE	DELIVERY MODE	
			03/12/2009	ELECTRONIC	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

patentdocket@oblon.com oblonpat@oblon.com jgardner@oblon.com

Application No. Applicant(s) 10/518,372 SHIOYA ET AL. Office Action Summary Examiner Art Unit Carolyn A. Paden 1794 -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS. WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status 1) Responsive to communication(s) filed on 05 February 2009. 2a) This action is FINAL. 2b) This action is non-final. 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. Disposition of Claims 4) Claim(s) 1-36 is/are pending in the application. 4a) Of the above claim(s) _____ is/are withdrawn from consideration. 5) Claim(s) _____ is/are allowed. 6) Claim(s) 1-36 is/are rejected. 7) Claim(s) _____ is/are objected to. 8) Claim(s) _____ are subject to restriction and/or election requirement. Application Papers 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are; a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. Priority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. Attachment(s)

1) Notice of References Cited (PTO-882)
2) Notice of Draftsperon's Patient Drawing Review (PTO-948)
3) Information-Disolocuse Statem-Nicky (PTO-SECE)
5) Notice of Information Patient Afficiation
5) Notice of Information Patient Afficiation
6) Other:

Application/Control Number: 10/518,372

Art Unit: 1794

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on February 5, 2009 has been entered.

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1-36 are rejected under 35 U.S.C. 103(a) as being unpatentable over Okawa (2002/0022062) for reasons of record.

Okawa discloses an extract of coffee beans used to prevent hypertension. The beans used for the extraction can be raw, decaffeinated or roasted and the remedy may be in the form of a powder, beverage, tablet or candy. In example 3, 3.6% coffee bean extract, which is from T. Hasegawa Co. is used with water, citric acid and vitamin C. In example 9 a medical vitamin drink is made containing the same coffee bean extract in

Art Unit: 1794

an amount of 350 mg in 50 ml water. The claims appear to differ from Okawa in the composition of the coffee bean extract. Applicant describes his coffee bean extract in example 20 as being from the same place as Okawa does (page 13, second to last line of specification) and refers to example 5 as a preferred embodiment. Further in the Specification at Table 1 the coffee bean extract is described as containing all of the components of the claims. It would have been obvious to one of ordinary skill in the art to expect the powdery food of Okawa to have the composition of the claims because it is made from the same ingredients. It is appreciated that the Brix content is not mentioned but coffee products are known in the art to be sweetened. No unobvious or unexpected result is seen from the specific Brix level that is used in the composition. To package a beverage would have been an obvious way to dispense the beverage. The chlorogenic acids of claims 13-25 and 31-34 are disclosed in Okawa in paragraph 0015.

Applicant argues and provides a declaration attesting to the fact that the ratio of hydroxycarboxylic acid to chlorogenic acid is 19.8 in example 9 of Okawa. Applicant urges unexpected improvement in taste when samples are prepared that maintains a specific ratio of hydroxycarboxylic

Application/Control Number: 10/518,372

Art Unit: 1794

acid to chlorogenic acids. This has been considered but is not persuasive because there is no requirement in Okawa for high levels of vitamin C be included. Examples 3 and 5 would be expected to have substantially lower levels of hydroxycarboxylic acid.

The rejection of the claims over Suzuki has been withdrawn.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Carolyn A Paden whose telephone number is (571) 272-1403. The examiner can normally be reached on Monday to Friday from 7 am to 3:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Keith Hendricks can be reached by dialing 571-272-1401. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have guestions on

Application/Control Number: 10/518,372

Art Unit: 1794

Page 5

access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/Carolyn Paden/

Primary Examiner 1794

.